Literature DB >> 21983813

Skin-specifically transgenic expression of biologically active human cytoxic T-lymphocyte associated antigen4-immunoglobulin (hCTLA4Ig) in mice using lentiviral vector.

Wen Jiang1, Xiao-Yang Zhou, Lu-lu Wang, Qin Liu, Cang'e Liu, Yong Wang, Hong Wei.   

Abstract

Xenogeneic skin, especially porcine skin, has already been used to cover large wounds in clinic practice of wound care. Our previous data showed that transgenic expression of human cytoxic T-lymphocyte associated antigen4-immunoglobulin (hCTLA4Ig) in murine skin graft remarkably prolonged its survival in xenogeneic burn wounds without extensive immunosuppression in recipients, suggesting that transgenic hCTLA4Ig expression in skin graft may be an effective and safe method to prolong its survival in xenogeneic wounds for coverage. Lentiviral transgenesis provides an extremely efficient and cost-effective method to produce transgenic animals. However, tissue-targeted transgenic expression of biologically functional protein by lentiviral transgenesis is rarely reported. In this work, a recombinant lentiviral vector (LV), named FKCW in this article, was constructed by inserting a skin-specific hCTLA4Ig expression cassette consisting of keratin 14 (K14) promoter, hCTLA4Ig coding sequence and an intronic fragment. Its efficacy for transgenesis and skin-specific expression of bio-active hCTLA4Ig protein was tested using mice as models. The LV FKCW was readily to be packaged and concentrated to high titres (1.287-6.254 × 10(9) TU/ml) by conventional lentivirus package system. Using eggs collected from only five mated females having been subjected to conventional super-ovulation treatment, 8 hCTLA4Ig transgenic founder mice were generated with the concentrated FKCW vector, and transgenic founder per injected and transferred egg was 6.3%, which was nearly 9-fold higher than that for DNA micro-injection with a similar transgene construct in our previous work. The lentiviral transgenic hCTLA4Ig exhibited strictly skin-specific expression at a level comparable to or even slightly higher than that of transgenic hCTLA4Ig delivered by micro-injection in a similar cassette. Lentiviral transgenic hCTLA4Ig protein remarkably suppressed human lymphocyte proliferation in vitro to a degree comparable to that of commercially purchased purified hCTLA4Ig protein with defined activity at similar concentrations. Besides, lentiviral hCTLA4Ig transgenic mouse skin grafted into rat burn wounds exhibited remarkably extended survival compared to wild-type skin of the same strain (13.8 ± 3.8 vs. 6.8 ± 3.0 days), indicating that lentiviral transgenic hCTLA4Ig did inhibit immune rejection against xenogeneic skin graft in vivo. These results laid down the foundation to further efficiently generate transgenic pigs skin-specifically expressing bio-active hCTLA4Ig by lentiviral transgenesis, and provided a demonstration that transgenic animals with tissue-targeted expression of biologically functional protein can be efficiently produced using LV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983813     DOI: 10.1007/s11248-011-9559-x

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  28 in total

Review 1.  Lentiviral transgenesis.

Authors:  Alexander Pfeifer
Journal:  Transgenic Res       Date:  2004-12       Impact factor: 2.788

Review 2.  A review of skin meshers.

Authors:  J Vandeput; M Nelissen; J C Tanner; J Boswick
Journal:  Burns       Date:  1995-08       Impact factor: 2.744

3.  Survival and wound contraction of full-thickness skin grafts are associated with the degree of tissue edema of the graft bed in immediate excision and early wound excision and grafting in a rabbit model.

Authors:  Yi Biao Wang; Yutaka Ogawa; Natsuko Kakudo; Kenji Kusumoto
Journal:  J Burn Care Res       Date:  2007 Jan-Feb       Impact factor: 1.845

4.  Expansion technique for skin grafts (Meek technique) in the treatment of severely burned patients.

Authors:  A R Lari; R K Gang
Journal:  Burns       Date:  2001-02       Impact factor: 2.744

Review 5.  Costimulation in tolerance and autoimmunity.

Authors:  S Guerder; R A Flavell
Journal:  Int Rev Immunol       Date:  1995       Impact factor: 5.311

6.  CTLA4-Ig abrogates the anti-globulin response and prolongs cardiac allograft survival after anti-CD2 treatment.

Authors:  David Stell; Hilary Marshall; J Andrew Bradley; Eleanor M Bolton
Journal:  Transpl Immunol       Date:  2003 Oct-Nov       Impact factor: 1.708

7.  Simultaneous blockade of co-stimulatory signals, CD28 and ICOS, induced a stable tolerance in rat heart transplantation.

Authors:  Lei Guo; Masayuki Fujino; Hiromitsu Kimura; Naoko Funeshima; Yusuke Kitazawa; Yasushi Harihara; Katsunari Tezuka; Masatoshi Makuuchi; Seiichi Suzuki; Xiao-Kang Li
Journal:  Transpl Immunol       Date:  2003 Oct-Nov       Impact factor: 1.708

8.  Quantitative analysis of lentiviral transgene expression in mice over seven generations.

Authors:  Yong Wang; Yong-tao Song; Qin Liu; Cang'e Liu; Lu-lu Wang; Yu Liu; Xiao-yang Zhou; Jun Wu; Hong Wei
Journal:  Transgenic Res       Date:  2010-01-22       Impact factor: 2.788

9.  Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.

Authors:  P S Linsley; P M Wallace; J Johnson; M G Gibson; J L Greene; J A Ledbetter; C Singh; M A Tepper
Journal:  Science       Date:  1992-08-07       Impact factor: 47.728

10.  Mammary gland-specific secretion of biologically active immunosuppressive agent cytotoxic-T-lymphocyte antigen 4 human immunoglobulin fusion protein (CTLA4Ig) in milk by transgenesis.

Authors:  Vincent C H Lui; Paul K H Tam; Michael Y K Leung; James Y B Lau; Jacqueline K Y Chan; Vera S F Chan; Margaret Dallman; Kathryn S E Cheah
Journal:  J Immunol Methods       Date:  2003-06-01       Impact factor: 2.303

View more
  1 in total

1.  Transgenic expression of human cytoxic T-lymphocyte associated antigen4-immunoglobulin (hCTLA4Ig) by porcine skin for xenogeneic skin grafting.

Authors:  Yong Wang; Hua-Qiang Yang; Wen Jiang; Na-Na Fan; Ben-Tian Zhao; Zhen Ou-Yang; Zhao-Ming Liu; Yu Zhao; Dong-Shan Yang; Xiao-Yang Zhou; Hai-Tao Shang; Lu-Lu Wang; Peng-Ying Xiang; Liang-Peng Ge; Hong Wei; Liang-Xue Lai
Journal:  Transgenic Res       Date:  2014-09-19       Impact factor: 2.788

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.